Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DYP688 in Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas
NCT05415072Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Jul 2022
- Primary completion
- Oct 2027
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 7
01
Overview
A Phase 2 trial of DYP688 in Uveal melanoma (UM), melanoma, sponsored by Novartis. Started Jul 2022; status: active, not recruiting.
02
Drugs
DYP688
03
Conditions
Uveal melanoma (UM)melanoma
Beyond the preview
Go deeper on NCT05415072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05415072.